Part of Sanofi, Aventis Pharma SARL is a French company located in Antony. The firm manufactures pharmaceuticals. It was founded in 1982.

Abraxis BioScience LLC, part of Bristol Myers Squibb Co., is a company headquartered in Los Angeles, CA, involved in commercial physical and biological research.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Chatham Biotec Ltd. provides active and raw agricultural ingredients from forest, farms and ocean. It specializes in fertilizer, nutraceutical and pharmaceutical ingredients, and industrial materials. The company was founded in 1994 and is headquartered in Riverview, Canada.

Indena is the world’s leading company in the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and personal care industries.Indena, a privately owned Italian company, has around 800 employees (10% of them dedicated to full-time research) and has cultivation, manufacturing, and sales in more than 70 countries throughout the world.

CritiTech conducts research and development into the production and application of fine-particle compounds. It has expanded its operations to include applications in fine particle api production, coatings, and internal product development. Their unique particle engineering innovation and expertise as well as their demonstrated experience in delivering high-quality, on-time results.

Since the establishment of Sunkyung Textiles in 1969, SK Chemicals has grown through continuous change and innovation into a chemical and life sciences enterprise representing South Korea. SK Chemicals’ new mission statement says, "They enhance human health and protect the Earth’s environment" and they have reorganized their business structure to focus on the two large sectors of green chemicals and life sciences. Providing distinguished chemical and life sciences products and solutions based on the world's highest technology standards, SK Chemicals is recognized as a leading global company of environmentally-friendly materials and total healthcare solutions. Their green chemical business is steadily progressing as a leading global company in the environmentally-friendly materials business by using the world’s best technology, knowledge, and production facilities. To achieve this goal, SK Chemicals has selected four new core areas of business: bio-materials, composites, high-performance materials, and energy saving materials while continuing a commitment to R&D activities.

Fidia Farmaceutici SpA manufactures pharmaceutical products. The firm's platform technology level is the chemical modification, development, and manufacturing of state-of-the-art pharmaceuticals and medical devices based on hyaluronan covering therapeutic categories. The company was founded in 1946 and is headquartered in Abano Terme, Italy.

A leader in therapeutic antibodies, ImClone Systems (also called "the company") is committed to advancing oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. Founded in 1984, ImClone has a rich culture of discovery and deep expertise in oncology. The company has utilized the many advances made in the fields of molecular biology, oncology, genomics, and antibody engineering to build a novel pipeline of product candidates designed to address specific genetic mechanisms involved in cancer growth and development. Beyond its blockbuster marketed product ERBITUX®, ImClone has several additional investigational monoclonal antibodies in various stages of clinical development. Following its acquisition by Eli Lilly and Company in 2008, ImClone Systems is accelerating its antibody pipeline development by leveraging Lilly's global capabilities. ImClone's pipeline has several molecules in mid- to late-stage clinical development targeting virtually all major solid tumor types. Additionally, ImClone plans to advance several additional targets from its research programs into clinical development over the coming years. ImClone's research and clinical development capabilities are augmented by its expertise in the scale-up and manufacturing of biologics. The company's state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, provide it with one of the largest biologic manufacturing capacities in the world. ImClone's Branchburg campus also houses it clinical development and administration operations. The company's research headquarters are based in New York City and it has international operations in Europe.

Teikoku Pharma USA, Inc. develops and manufactures drugs. It provides patches, unit-dose jellies and liquids, creams, ointments, and other delivery products for pain management and cosmetic care. The company was founded by Masahisa Kitagawa and Ichiro Mori in 1997 and is headquartered in San Jose, CA.

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Piramal Enterprises Ltd. engages in the business of pharmaceuticals and provision of financial services. It operates through the following segments: Pharmaceuticals Manufacturing and Services, Financial Services, and Healthcare Insights and Analytics. The Pharmaceuticals Manufacturing and Services segment operates through the following divisions: Pharma Solutions, Critical Care, Consumer Products Services and Imaging. The Financial Services segment offers a complete suite of financial products to meet the diverse needs of its customers. The Healthcare Insights and Analytics segment provides indispensable insights to life sciences companies as well as healthcare providers and payers through a variety of high value-added data and analytics, research reports, and knowledge-based services. The company was founded on April 26, 1947 and is headquartered in Mumbai, India.

AstraZeneca has always believed in science, inspires infinite possibilities, and puts science at the top of all work. AstraZeneca's strategically important core treatment areas, and are committed to exploring pathogenic mechanisms, treatment methods, and innovative drugs, so that science can change people's lives and bring it to the medical industry Significant changes.

Ensuiko Sugar Refining Co., Ltd. engages in the manufacture and sale of refined sugar. It operates through the following segments: Sugar, Bio, and Others. The Sugar segment deals with the production and sale of sugar products such as granulite sugar, white sugar, and liquid sugar. The Bio segment handles the manufacture and sale of lactose and fructose oligosaccharides and cyclodextrins. The Others segment manages the leasing of a portion of the company building to third parties. The company was founded in February 1904 and is headquartered in Tokyo, Japan.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Acusphere is a specialty pharmaceutical company, primarily focused on the development of Imagify™ (perflubutane polymer microspheres) injectible suspension, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional trial required for U.S. approval. Imagify was created using Acusphere’s proprietary porous microparticle technology, which was also used to create three other drugs which have begun clinical development – AI-525 for acute pain, AI-850 for oncology and AI-128 for asthma. AI-525 and AI-850 were sold to Cephalon in transactions totaling $31 million. AI-128 was developed in collaboration with Elan, who contributed $7.5 million to the program. Acusphere’s technology has the potential to create a wide variety of new drugs by reformulating hydrophobic drugs and creating sustained release formulations of existing drugs.